[Clinical study of early interventions for ABO hemolytic disease of the newborn]. To investigate therapeutic effect of high-dose intravenous immunoglobulin (IVIG) for early management of ABO hemolyticdisease of the newborn (ABO-HDN). A total of 121 cases with ABO-HDN were randomly divided into treatment group (n=61) and control group (n=60). In addition to the routine treatment of the control
Treatment of ABO hemolytic disease with synthetic blood group trisaccharides. Thirteen infants, 10 with A-O and 3 with B-O hemolyticdisease of the newborn (ABO-HDN), were treated with synthetic A or B blood group trisaccharides (ATS, BTS) which cause dissociation of maternal antibody bound to infant red cells. The clinical outcome was compared with that of a control group of 21 infants treated